TOP TEN perturbations for 1553292_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553292_s_at
Selected probe(set): 1553292_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553292_s_at (1553292_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.4524097Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.2347136Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.8498936Number of Samples:3 / 3
Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.4839258Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):2.4506035Number of Samples:9 / 12
Experimental | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):-2.3919034Number of Samples:8 / 9
Experimental | hepatocyte (ESC) |
Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
Control | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
brain tumor study 1 (medulloblastoma) / brain tumor study 1 (ependymoma)
Relative Expression (log2-ratio):2.3912039Number of Samples:22 / 46
Experimental | brain tumor study 1 (medulloblastoma) |
Primary tumor tissue sample from the brain of patients with medulloblastoma. | |
Control | brain tumor study 1 (ependymoma) |
Primary tumor tissue sample from the brain of patients with ependymoma. |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):2.3422203Number of Samples:2 / 2
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.3385582Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
OXPHOS disorder study 1 (old) / control muscle (old)
Relative Expression (log2-ratio):2.3349285Number of Samples:2 / 2
Experimental | OXPHOS disorder study 1 (old) |
Skeletal muscle biopsies obtained from young patients (50 and 68 years old) with oxidative phosphorylation system deficiency (OXPHOS disorder). All patients exhibited mutations in the catalytic DNA polymerase gamma (POLG1) gene. | |
Control | control muscle (old) |
Skeletal muscle biopsies obtained from control old subjects that were 53 and 64 years old. |